Fisher and Paykel Healthcare (NZX: FPH) is widely regarded by institutional analysts as a high-quality global medical device manufacturer, though whether it is an immediate "buy" depends on current valuation multiples. Proponents highlight its dominant position in respiratory humidification products, robust research and development pipelines, and strong balance sheet, while cautious voices point to premium pricing valuations.